Ombitasvir / paritaprevir / ritonavir / dasabuvir  ±  ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .

DSpace/Manakin Repository

Ombitasvir / paritaprevir / ritonavir / dasabuvir  ±  ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .

Show simple item record

dc.contributor.author Mendizabal, Manuel.
dc.contributor.author Haddad, Leila.
dc.contributor.author Gallardo, Patricia.
dc.contributor.author Ferrada, Alejandro.
dc.contributor.author Soza, Alejandro.
dc.contributor.author Adrover, Raul.
dc.contributor.author Aravena, Edmundo.
dc.date.accessioned 2020-02-19T17:50:57Z
dc.date.available 2020-02-19T17:50:57Z
dc.date.issued 2017-03-29
dc.identifier.citation J Med Virol. Septiembre de 2017; 89 (9): 1590-1596. en_US
dc.identifier.issn 0146-6615
dc.identifier.uri https://riu.austral.edu.ar/handle/123456789/819
dc.description.abstract Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real-world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child-Pugh B at baseline and one patient died due to multi-organ failure. Follow up HCV-RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child-Pugh A cirrhosis in non-European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child-Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region. en_US
dc.language.iso en en_US
dc.publisher Wiley en_US
dc.subject Antiviral agents en_US
dc.subject Disease control en_US
dc.subject Hepatitis C virus en_US
dc.subject Public policy en_US
dc.title Ombitasvir / paritaprevir / ritonavir / dasabuvir  ±  ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina . en_US
dc.type Article en_US


Files in this item

Files Size Format View Description
J Med Virol. 2017 Sep;89(9);1590-1596..pdf 114.0Kb PDF View/Open IA - Mendizabal

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account